A pragmatic definition of therapeutic synergy suitable for clinically relevant in Vitro multicompound analyses

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1964-1976

  Kashif, Muhammad ^a   Andersson, Claes ^a   Åberg, Magnus ^a,b   Nygren, Peter ^c   Sjöblom, Tobias ^d   Hammerling, Ulf ^a   Larsson, Rolf ^a   Gustafsson, Mats G ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Engineering Sciences   (Sweden)

^c Department of Radiology Oncology and Radiation Sciences ^*  (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EIC 600; EIC600; ERLOTINIB; FLUOROURACIL; OXALIPLATIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; PHARMACOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; THEORETICAL MODEL; THERAPEUTIC SYNERGY; BIOLOGICAL MODEL; DRUG COMBINATION; DRUG POTENTIATION; HCT116 CELL LINE; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HCT116 CELLS; HUMANS; MODELS, BIOLOGICAL;

EID: 84904161049     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0430     Document Type: Article

References (32)

1. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A 2003;100:7977-82. (Pubitemid 36760080)
2. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005;4:71-8. (Pubitemid 40109591)
3. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649-59. (Pubitemid 44151603)
4. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006;2:458-66. (Pubitemid 44266307)
5. Zimmermann GR, Lehá J, Keith CT. Multitarget therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12:34-42. (Pubitemid 46014485)
6. Lehá J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 2007;3:80.
7. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331-85.
8. Loewe S, Muischnek H. Uber Kombinationswirkungen. I. Mitteilung Hilfsmittel der Fragestellung. Arch Exp Path Pharmakol 1926;114:313-26.
9. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953;3:285-90.
10. Bliss CI. The toxicity of poisons applied jointly, Ann Appl Biol 1939;26:585-615.
11. Box GEP. The exploration and exploitation of response surfaces: some general considerations and examples. Biometrics 1954;10:16-60.
12. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141. (Pubitemid 20019599)
13. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
14. Berenbaum MC, Dale JW. Synergy and antagonism are not synonymous with therapeutic advantage and disadvantage. J Antimicrob Chemo Ther 1988;21:497-500.
15. Greco WR, Faessel H, Levasseur L. The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers? J Natl Cancer Inst 1996;88:699-700.
16. Venditti JM, Humphreys SR, Mantel N, Goldin A. Combined treatment of advanced leukemia (L1210) in mice with amethopterin and 6-mercaptopurine. J Nat Cancer Inst 1956;17:631-8.
17. Goldin A, Venditti JM, Mantel N, Kline I, Gang M. Evaluation of combination chemotherapy with three drugs. Cancer Res 1968;28:950-60.
18. Mantel N. Therapeutic synergism. Cancer Chemother Rep 1974;4:147-9.
19. Carter WH, Wampler GL, Stablein DM, Campbell ED. Drug activity and therapeutic synergism in cancer treatment. Cancer Res 1982;42:2963-71. (Pubitemid 12041036)
20. Goldin A, Mantel N. The employment of combinations of drugs in the chemotherapy of neoplasia: a review. Cancer Res 1957;17:635-54.
21. Nelder JA, Mead R. A simplex method for function minimization. Comput J 1965;7:308-13.
22. Carter WH, Wampler GL, Crews SL, Howells R. On determining the levels of treatment to optimize the probability of a favorable response. Cancer Treat Rep 1977;61:849-53.
23. Wampler GL, Carter WH, Williams VR. Combination chemotherapy: arriving at optimal treatment levels by incorporating side effect constraints. Cancer Treat Rep 1978;62:333-40. (Pubitemid 8335895)
24. Carter WH, Stablein DM, Wampler GL. An improved method for analyzing survival data from combination chemotherapy experiments. Cancer Res 1979;39:3446-53. (Pubitemid 9255763)
25. Stablein DM, Carter WH, Wampler GL. Confidence regions for constrained optima in response-surface experiments. Biometrics 1983;39:759-63.
26. Carter WH, Wampler GL, Stablein DM. Regression analysis of survival data in cancer chemotherapy. New York, NY: Marcel Dekker; 1983.
27. Shih M, Gennings C, Chinchilli VM, Carter WH. Titrating and evaluating multidrug regimens within subjects. Stat Med 2003;22:2257-79. (Pubitemid 36926939)
28. Zanderigo E, Sartori V, Sveticic G, Bouillon T, Schumacher P, Curatolo M, et al. A new model for drug interactions and optimal drug dosing. Conf Proc IEEE Eng Med Biol Soc 2005;3:2353-6. (Pubitemid 46229387)
29. Zanderigo E, Sartori V, Sveticic G, Bouillon T, Schumacher P, Morari M, et al. The well-being model: a new drug interaction model for positive and negative effects. Anesthesiology 2006;104:742-53.
30. Lindhagen E, Nygren P, Larsson R. The fluorometric microculture cytotoxicity assay. Nat Protoc 2008;3:1364-9.
31. R Development Core Team. R: a language and environment for statistical computing. 2011. R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0. Available from: www.R-project.org.
32. Laska EM, Meisner M, Tang DI. Classification of the effectiveness of combination treatments. Stat Med 1997;16:2211-28. (Pubitemid 27429767)